Description: Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Nirma Limited.
Home Page: www.glenmarklifesciences.com
OIA House
Mumbai,
400099
India
Phone:
91 22 6829 7979
Officers
| Name | Title |
|---|---|
| Dr. Yasir Yusufali Rawjee Ph.D. | CEO, MD & Director |
| Mr. Tushar P. Mistry | Senior VP & CFO |
| Mr. Vinod Naik | Group VP, Head of Technical Operations & Whole Time Director |
| Mr. Rudalf Corriea | Company Secretary & Compliance Officer |
| Soumi Rao | General Manager of Corporate Communications |
| Mr. Sumantra Mitra | Senior VP & Head of Human Resources |
| Mr. Mathew George | Senior VP & Head of Regulatory Affairs |
| Mr. Navin Kumar Agrawal | VP & Head of Corporate Quality |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 30.678 |
| Price-to-Book MRQ: | 5.1 |
| Price-to-Sales TTM: | 5.9102 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 2014 |